ArticleComputational and structural biotechnology journal2025
Molecular investigation of ergot alkaloid ergotamine's modulatory effects on glycine receptors expressed in
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between oxidative stress and glycine receptors is complex, involving multiple mechanisms through which reactive oxygen species can modify glycine receptor function. Understanding these interactions is essential for developing therapeutic strategies to mitigate the effects of oxidative stress on inhibitory neurotransmission in various neurological disorders. Inhibitory glycine receptors play a critical role in regulating the final grand postsynaptic potential by attenuating excitatory postsynaptic potentials through inhibitory postsynaptic potentials in postsynaptic neurons. This is particularly important in rapid signal transmission systems, where it determines whether the grand postsynaptic potential exceeds the activation threshold. Glycine receptors are known to be expressed not only in the spinal cord and brainstem but also in the hippocampus, as evidenced by studies conducted over the past decade. Interestingly, these regions share a common cellular architecture, predominantly composed of pyramidal neurons. In hippocampal pyramidal neurons, glycine receptors contribute to the regulation of synapse formation and plasticity, and they are crucial in motor neuron control within the pyramidal tract. However, there is limited research on glycine receptor antagonism, which is necessary to fully understand their biological functions in these regions. We conducted a comprehensive molecular-level analysis of the pharmacological properties of glycine receptors, examined their interaction mechanisms through electrophysiological studies, and identified binding sites using structural modeling and site-directed mutagenesis. Our findings suggest that ergotamine may serve as a promising antioxidant candidate to address issues associated with excessive or prolonged inhibitory postsynaptic potentials, offering a potential new therapeutic pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.